Loading
Loading
Research Overview
Potent NNMT (nicotinamide N-methyltransferase) inhibitor; NNMT normally consumes methyl donors that would otherwise support NAD+ synthesis, so its inhibition raises intracellular NAD+ and SAM levels, increasing mitochondrial activity and reducing lipid accumulation in preclinical models.
5-Amino-1MQ is a cell-permeable NNMT inhibitor studied in preclinical settings for its ability to reduce NNMT enzymatic activity and alter NAD+ metabolism. By inhibiting NNMT, the compound reduces nicotinamide catabolism, potentially elevating intracellular NAD+ pools and influencing sirtuin activity, epigenetic methyl donor availability, and adipocyte biology.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, 5-amino-1mq (nnmt inhibitor) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
5-Amino-1MQ (NNMT Inhibitor) research is most relevant to protocols examining:
NNMT inhibition and NAD+ elevation research
Metabolic syndrome and insulin resistance studies
Researchers seeking oral fat loss compounds without GLP-1 mechanisms
Methyl donor biology and epigenetic metabolism research
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Potent NNMT (nicotinamide N-methyltransferase) inhibitor; NNMT normally consumes methyl donors that would otherwise support NAD+ synthesis, so its inhibition raises intracellular NAD+ and SAM levels, increasing mitochondrial activity and reducing lipid accumulation in preclinical models.
| Parameter | Value |
|---|---|
| Dose range | 50–100 mg/day |
| Schedule | Daily |
| Route | Oral |
| Half-life | ~Hours |
nausea, bloating)
Community & Anecdotal Signal
Community signal is thin and quality-variable. 5-Amino-1MQ occupies a similar early-adopter position to SLU-PP-332, with limited personal experience reports and discussion that often conflates different compounds in the NNMT inhibitor class. Fat loss and metabolic support are the primary framing in community discussion, driven by the mechanism rather than accumulated outcome data. r/Peptides threads exist but are short. Sourcing reliability concerns are prominent given the compound's niche status and limited commercial history. The community interested in 5-Amino-1MQ tends to be highly researc
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
